Tag: pharmaceuticals
-
Core One Labs (COOL.C): Out of the ashes, a new business model and supportive shareholder base
In my experience with the North American public markets, few companies and executive teams got more lucky with their shareholder base than Lifestyle Delivery Systems. Their initial pitch was simple – they’d put extracted cannabis on thin film strips for easy and precise ingestion – and I, along with a ton of others, shoveled money…
-
![Revive (RVV.C) stock ramps hard on news from a collaborator]()
Revive (RVV.C) stock ramps hard on news from a collaborator
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”.
-
Sixth Wave (SIXW.C) partners with super-star research institution – potential pipeline accelerator
Dr. Houghton – a Director and Research Chair holder at Li Ka Shing – just won a Nobel Prize.
-
![Revive (RVV.C) advances mushroom bio-tech as new regs change the game]()
Revive (RVV.C) advances mushroom bio-tech as new regs change the game
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison”. RVV is a specialty life sciences company focused on the R&D of therapeutics for medical needs and rare disorders.…
-
![Sixth Wave (SIXW.C) gets $250,000 Covid-19 development money from Nova Scotia]()
Sixth Wave (SIXW.C) gets $250,000 Covid-19 development money from Nova Scotia
SIXW is a nanotechnology company focusing on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs).
-
Revive Therapeutics (RVV.C) to have 10 clinical COVID-19 FDA trial sites by end of year
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks laughed uproariously at the thought that a three time loser might be relevant in 2020. Having missed on an earlier pharma focus, and come to the cannabis party a little…
-
Aequus Pharmaceuticals (AQS.V) gets Health Canada device licence approval, validates business model
Aequus Pharmaceuticals (AQS.V), a specialty pharma company with a business model of acquiring and re-platforming existing approved biotech and health products to appeal to a wider market, has announced another win Monday morning with news Health Canada has approved the advancing of their Evolve dry-eye relief gel line to an easy-squeeze eye drop bottle. Admittedly,…
-
![How Sixth Wave (SIXW.C) plans to “protect and detect” for COVID-19]()
How Sixth Wave (SIXW.C) plans to “protect and detect” for COVID-19
Sixth Wave is a nanotechnology company focusing on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs).
-
Revive (RVV.C) gives update on FDA Phase 3 clinical trial
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focused on developing coronavirus solutions.
-
Bio-tech without the dice roll: Aequus Pharmaceuticals (AQS.V) building a solid, multi-pronged revenue earner
For the last several years, a lot of stories I’ve written on this site have been about promise. The promise of something better, cheaper, with more upside, with less downside. Promise that a team will do more, or do better, or do something – anything. Promise that, if the planets align, something big will come.…
